The Bill Gates Foundation-backed partnership with IAVI could bring a HIV vaccine a step closer, but generating the right antibody response has defeated many previous attempts.
Moderna believes its mRNA know-how, which has proven so successful against COVID-19, could also help finally crack the challenge of developing a HIV vaccine, and has just launched a Phase I study with academic partners.
While antiretroviral therapies are able to suppress HIV for a lifetime once individuals are infected, there remains a need for...
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
